SynthesisJournal of cardiovascular electrophysiology2025
Contemporary Outcomes of Ventricular Tachycardia Ablation in Left Ventricular Assist Device Therapy: A Meta-Analysis.
Synthesis in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in mapping, cardiac imaging, and ablation techniques for the management of ventricular tachycardias.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
objectiveVentricular arrhythmias (VAs) remain a pervasive and deadly arrhythmia in patients with left ventricular assist devices (LVADs). Catheter ablation has emerged as a treatment option for refractory VAs, yet evidence in the era of the HeartMate 3 (HM3) remains limited. This review aims to synthesize contemporary evidence for VA ablation in LVAD recipients.
methodsA systematic review was performed across major electronic databases. The primary efficacy outcome was the recurrence of ventricular tachycardia (VT), and the primary safety outcome was the rate of procedural complications. The secondary outcomes were inability to induce any VT, all-cause mortality at 12 months, orthotropic heart transplantation (OHT). Sub-analyses were performed for patients with HM3 LVADs.
resultsTwenty-seven studies encompassing 300 LVAD recipients undergoing 325 VT ablations, after a mean follow-up of 327 ± 175 days post VT ablation, VT recurred in 38% (95% CI, 28% to 49%) of cases and the complication rate was 8% (95% CI, 1.6% to 15.7%). VT was non-inducible in 61% of cases. One-year all-cause mortality was 26%, and 16% had OHT. Among HM3 recipients, electromagnetic interference (EMI) occurred in 51%, and no cases of device thrombosis were reported; one stroke was observed.
conclusionsCatheter ablation is a safe and feasible treatment for refractory VAs in LVAD patients as evidenced by low complication rates and reasonable acute success. Yet, the persistence of considerable VT recurrence and all-cause mortality reflects the clinical complexity of this population. Procedural challenges include mapping limitations caused by EMI, particularly in the HM3 era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.